Finance 3h ago 1 min read
Abivax $ABVX fell more than 30% after investors focused on cancer-case details in Phase 3 ABTECT maintenance data, despite placebo-adjusted clinical remission rates of 39.3% and 40.3% for 25 mg and 50 mg obefazimod. The company still targets an FDA NDA submission in late Q4 2026.